Pengobatan Malaria Melalui Target Enzim

Sri Sundari

Abstract


Plasmodium falciparum causes the most severe form of malaria which is fatal in many cases. The emergence of drug-resistant strains of P. falciparum to the standard therapy of malaria (i.e. kloroquin) requires the new drug en¬zyme targets to be identified. This review covers in details: the enzymes of purin salvage pathway; pyrimidine biosynthesis; protease involved in catabo¬lism on haemoglobin. The review also briefly touches upon other potential targets in the treatment of malaria falciparum.
k
Plasmodium falciparum menyebabkan bentuk penyakit malaria yang paling berat yang menyebabkan kematian dalam banyak kasus. Munculnya strain-strain P. falciparum yang resisten obat antimalaria (yaitu klorokuin) mengharuskan untuk menggali target enzim obat baru yang dapat digunakan untuk pengobatan malaria. Tinjauan ini membicarakan secara detil tentang: enzim-enzim dalam proses metabolisme purin; biosintesis pirimidin dan protease yang terlibat dalam katabolisme hemoglobin. Selain itu, secara singkat tinjauan ini juga akan membicarakan tentang target enzim potensial lainnya untuk terapi malaria falciparum.

Keywords


target obat; plasmodium falcifarum; prosses metabolisme purin; biosintesis pirimidin; protease; drug targets; Plasmodium falciparum; purine salvage pathway; pyrimidine biosynthesis; protease

Full Text:

PDF

References


Bergmman PA., Human L, freese JA., 1991. Xanthine oxydase inhibits growth of Plasmodium falciparum in human erithrocytes in vitro. J. Clin. Invest. 88:1848-55.

Carlson J, Helmby H, Hill AV., Brewser D, Greenwood BM., Wahlgren M. 1990. Human cerebral malaria: association with erithrocyte rosseting and lack of anti-rosetting antibodies. Lancet. 336:1457-60.

Fry M, Pudney M. 1992. Site of action of the antimalarial hydroxunapthoquinone, 2-(tran-4-(4‘- chlorophenyl)cuclohexyl)-3-hydroxy-l, 4-napthoquinone (566C80). Biochem Parmacol. 43:1545-53

Gero AM., Brown GV., Sullivan WJ. 1984. Pyrimidine de novo synthesis during the life cycle of the intraerithrocytic stage of Plasmodium falciparum. J. Parasitol. 9:66-8.

Goldberg DE, Slater AF, Beavis R, Chait B, Cerami A, Haenderson GB. 1991. Hemoglobin degrada¬tion in human malaria phatogen Plasmodium falciparum: A catabolic pathway initiated by a specific aspartic protease. J. Exp. Med. 173:961-9.

Gluzman IY, Francis SE, Oksman A, Smith CE, Daffin KL, Goldberg DE. 1994. Order and the specificity of the Plasmodium falciparum haemoglobin degradation pathway. J. Clin. Invest. 93:1602-8.

Hammond D.J, Burchell J.R, Pudney M. 1985. Inhibition of Pyrimidine biosynthesis de novo in Plasmodium falciparum by 2-(4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone in vitro. MolBiochem. Parasitol. 14:97-109

Hudson A.T. 1993. Atovaquon - A novel broad spectrum antiinfective drug. Parasitol Today, 9:66-8.

McKerrow JH, Sun E, Rosenthal PJ, Bouvier J. 1994. The protease and pathogenicyti of parasitic protozoa. Annu Rev. Microbiol. 47:821-53.

Reyes P, Rathod PK, Sanchez DJ, Mrema JE, Rieckmann KH, Heidrich HG. 1982. Enzymes of purine and pyrimidine metabolism from the human malaria parasite Plasmodium falciparum. Mol biochem Parasitol. 5:275-90.

Rosenthal PJ, Lee GK, Smith RE. 1993. Inhibition of Plasmodium vinckei cystein proteinase cures murine malaria. Jclin Invest. 91:1052-6.

Rosenthal PJ, Wollish WS, Palmer JT, Rasnick D. 1991. Antimalarial effects of peptides inhibitors of a Plasmodium falciparum cystein proteinase. J clin Invest. 88:1467-72.

Webster HK, Wiesmann WP, Pavia CS. 1984. Adenosine deaminase in malaria infection: effect of 2‘- deoxycoformycin in vivo. Adv. Exp Med biol. 165:225-9.

WHO, 2000. Malaria Control. WHO Plan of Action 2000-2001, World Health Organization Represen¬tative to Indonesia Internet.

WHO. 2001. Malaria in Indonesia: Prevention and Treatment. Internet. 1-5.




DOI: https://doi.org/10.18196/mmjkk.v1i2.1905

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

      

Editorial Office:
Journal Room, G1 (Biomedic) Building, Ground Floor, Faculty of Medicine and Health Science Universitas Muhammadiyah Yogyakarta, 
Jalan Lingkar Selatan (Brawijaya), Tamantirto, Kasihan, Bantul, Daerah Istimewa Yogyakarta, Indonesia
Phone: +62 274 387 656 (ext: 231)
WA : +62 811-2650-303
Website: http://journal.umy.ac.id/index.php/mm 
E-mail: mmjkk@umy.university

Creative Commons License
Mutiara Medika: Jurnal Kedokteran dan Kesehatan is licensed under a Creative Commons Attribution 4.0 International License. View My Stats